[Stents in interventional cardiology].

Area of Science:

• Interventional Cardiology
• Cardiovascular Disease Research
• Medical Device Technology

Background:

• Percutaneous coronary interventions (PCI) are primary treatments for coronary heart disease.
• Early angioplasty faced challenges with dissections and restenosis.
• Coronary stenting, introduced in 1994, significantly reduced restenosis rates compared to balloon angioplasty.

Purpose of the Study:

• To review the evolution and impact of coronary stenting, particularly drug-eluting stents (DES).
• To discuss the benefits and limitations of DES in managing coronary artery disease.
• To highlight current recommendations for DES utilization in interventional cardiology.

Main Methods:

• Review of historical data and landmark trials (STRESS, BENESTENT).
• Analysis of subacute stent thrombosis and restenosis rates.
• Evaluation of drug-eluting stent efficacy versus bare-metal stents.
• Consideration of long-term outcomes and patient-specific factors (e.g., diabetes).

Main Results:

• Drug-eluting stents drastically lower restenosis rates (3-5%) in native coronary arteries.
• Subacute stent thrombosis (1-2%) is a concern, managed with dual antiplatelet therapy.
• Long-term studies show comparable major adverse cardiac events between DES and bare-metal stents, especially in diabetic patients with bifurcational lesions.
• DES are recommended for small vessels, restenotic lesions, and saphenous vein grafts.

Conclusions:

• Drug-eluting stents represent a major advancement in interventional cardiology, improving restenosis rates.
• While effective, DES require careful consideration of prolonged antiplatelet therapy and long-term outcomes.
• Ongoing improvements and specific indications suggest continued advancement in coronary stenting technology.